These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 30407350)

  • 41. [A Case of Hydrocephalus Due to Brain Metastasis from Renal Cell Carcinoma Successfully Treated with Axitinib].
    Shimura S; Koguchi D; Minamida S; Taoka Y; Iwamura M
    Hinyokika Kiyo; 2017 Jan; 63(1):11-14. PubMed ID: 28245539
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [A case of renal cell carcinoma with lung metastasis and local recurrence effectively treated with nephrectomy and UFT].
    Taguchi H; Takaoka K; Matsuda M
    Gan To Kagaku Ryoho; 1992 Dec; 19(14):2395-8. PubMed ID: 1463346
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A Case Report : Metastatic Carcinoma of the Collecting Ducts of Bellini in a Hemodialysis Patient Treated with Temsirolimus].
    Akahane M; Nakashima M; Sakamoto H; Aoyama T; Kawai J
    Hinyokika Kiyo; 2017 Jun; 63(6):239-243. PubMed ID: 28694417
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.
    Beckermann KE; Jolly PC; Kim JY; Bordeaux J; Puzanov I; Rathmell WK; Johnson DB
    J Immunother Cancer; 2017; 5():1. PubMed ID: 28105368
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A Case of Rheumatoid Arthritis Developed during Treatment with Nivolumab for Renal Cell Carcinoma].
    Tomizawa M; Nakai Y; Maesaka F; Owari T; Hara R; Miyake M; Inoue T; Anai S; Tanaka N; Fujimoto K
    Hinyokika Kiyo; 2018 Oct; 64(10):397-401. PubMed ID: 30543737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
    Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
    Front Immunol; 2022; 13():984132. PubMed ID: 36189265
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PD-L1 detection using
    Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
    J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [METASTATIC Mucinous Tubular and Spindle Cell Carcinoma Treated with Nivolumab Successfully : A Case Report].
    Takahashi Y; Numakura K; Aoyama Y; Okada S; Saito T; Muto Y; Koizumi A; Nara T; Chiba S; Kanda S; Saito M; Narita S; Inoue T; Satoh S; Nanjo H; Habuchi T
    Hinyokika Kiyo; 2019 Sep; 65(9):363-367. PubMed ID: 31697878
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
    Oudard S; Banu E; Vieillefond A; Fournier L; Priou F; Medioni J; Banu A; Duclos B; Rolland F; Escudier B; Arakelyan N; Culine S;
    J Urol; 2007 May; 177(5):1698-702. PubMed ID: 17437788
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [PATHOLOGICAL COMPLETE RESPONSE WITH EVEROLIMUS FOR MULTIPLE LUNG METASTASES OF RENAL CELL CARCINOMA RESISTANT TO SUNITINIB].
    Namura K; Otake S; Sawada T; Fujikawa A; Ota J; Moriyama M
    Nihon Hinyokika Gakkai Zasshi; 2015 Jan; 106(1):30-4. PubMed ID: 26399128
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
    Amin A; Plimack ER; Ernstoff MS; Lewis LD; Bauer TM; McDermott DF; Carducci M; Kollmannsberger C; Rini BI; Heng DYC; Knox J; Voss MH; Spratlin J; Berghorn E; Yang L; Hammers HJ
    J Immunother Cancer; 2018 Oct; 6(1):109. PubMed ID: 30348216
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
    Choueiri TK; Kluger H; George S; Tykodi SS; Kuzel TM; Perets R; Nair S; Procopio G; Carducci MA; Castonguay V; Folefac E; Lee CH; Hotte SJ; Miller WH; Saggi SS; Lee CW; Desilva H; Bhagavatheeswaran P; Motzer RJ; Escudier B
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.
    Cella D; Grünwald V; Nathan P; Doan J; Dastani H; Taylor F; Bennett B; DeRosa M; Berry S; Broglio K; Berghorn E; Motzer RJ
    Lancet Oncol; 2016 Jul; 17(7):994-1003. PubMed ID: 27283863
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
    Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
    Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy.
    Anraku T; Hashidate H; Nakahara A; Imai T; Kawakami Y
    BMC Urol; 2023 Mar; 23(1):38. PubMed ID: 36934227
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.
    Albiges L; Powles T; Staehler M; Bensalah K; Giles RH; Hora M; Kuczyk MA; Lam TB; Ljungberg B; Marconi L; Merseburger AS; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Bex A
    Eur Urol; 2019 Aug; 76(2):151-156. PubMed ID: 31151678
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [A case of Bellini collecting duct carcinoma with hypercalcemia in a young adult].
    Kamimura Y; Segawa T; Masuda N; Utsunomiya N; Muguruma K; Kawakita M
    Hinyokika Kiyo; 2012 Feb; 58(2):83-6. PubMed ID: 22450834
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Left ventricular dysfunction associated with axitinib and nivolumab experience in an advanced renal cell carcinoma.
    Tanriverdi O; Ates S; Sandal KK; Uylas S; Bosna IC; Alkan A
    J Oncol Pharm Pract; 2020 Oct; 26(7):1765-1768. PubMed ID: 32164490
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.
    George S; Motzer RJ; Hammers HJ; Redman BG; Kuzel TM; Tykodi SS; Plimack ER; Jiang J; Waxman IM; Rini BI
    JAMA Oncol; 2016 Sep; 2(9):1179-86. PubMed ID: 27243803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.